oritavancin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Targanta Therapeutics's portfolio.
pharma · Staphylococcal Skin Infections
Targanta Therapeutics
Targanta Netherlands B.V.
Targanta Therapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
63 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 63
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Targanta Therapeutics pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Targanta Therapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.